Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer PatientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study evaluated whether taking probiotics after surgery could reduce gastrointestinal complications and correct gut microbiota disturbances caused by chemotherapy in colorectal cancer (CRC) patients. Researchers compared a probiotic combination against a placebo, given from the post-operative period through the end of the first chemotherapy course. Gastrointestinal symptoms including nausea, acid reflux, abdominal pain, abdominal distention, constipation, and diarrhea were tracked throughout treatment. Fecal samples were analyzed using 16S rRNA high-throughput sequencing and short-chain fatty acid (SCFA) measurement to assess microbiota changes.
Who was studied?
One hundred eligible CRC patients who underwent radical surgery and required subsequent chemotherapy were recruited for this study. Participants were randomly assigned to two equal groups of fifty: a Probio group receiving the probiotic combination, and a Placebo group receiving placebo instead. Fecal samples were collected from these patients at two time points, preoperatively and after the first postoperative chemotherapy cycle.
What were the most important findings?
Probiotic administration effectively reduced chemotherapy-induced gastrointestinal complications, with a particularly strong effect on diarrhea (p < 0.01). Chemotherapy alone reduced the bacterial diversity of the gut microbiota in these CRC patients. This chemotherapy-induced loss of microbial diversity was significantly reversed by probiotic supplementation, indicating a protective effect on the gut ecosystem during treatment.
What are the greatest implications of this study?
These findings suggest that postoperative probiotic supplementation could be a practical, low-risk strategy to improve chemotherapy tolerability in colorectal cancer patients. By reducing diarrhea and preserving gut microbial diversity, probiotics may help patients complete chemotherapy regimens with fewer disruptive side effects. This supports considering probiotic co-administration as part of standard supportive care during postoperative chemotherapy for CRC.